LQDA
Liquidia Corporation [LQDA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LQDA Stock Summary
Top 10 Correlated ETFs
LQDA
Top 10 Correlated Stocks
LQDA
In the News
LQDA Financial details
Company Rating
-
Market Cap
1.06B
Income
-79.89M
Revenue
17.49M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
145
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-14.62
Forward P/E
-
PEG
-1.56
P/S
49.18
P/B
17.79
P/C
-
P/FCF
-21.57
Quick Ratio
6.55
Current Ratio
6.83
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.22
EPS next Y
-
EPS next Q
-
EPS this Y
92.06%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-13.58%
Revenue last 5Y
16.72%
Revenue Q/Q
23.19%
EPS Q/Q
75%
-
-
-
-
SMA20
25.38%
SMA50
44.25%
SMA100
62.19%
Inst Own
-
Inst Trans
-
ROA
-52%
ROE
22%
ROC
-0.54%
Gross Margin
86%
Oper. Margin
-292%
Profit Margin
-319%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
5.71-16.99
52W High
+0.69%
52W Low
+222.2%
RSI
68.66
Rel Volume
0.6
Avg Volume
925.76K
Volume
558.36K
Perf Week
-0.92%
Perf Month
29.92%
Perf Quarter
68.87%
Perf Half Y
61.42%
-
-
-
-
Beta
0.194
-
-
Volatility
0.16%, 1.59%
Prev Close
-2.36%
Price
16.11
Change
-2.19%
Company Profile
- Volume Average 925.76K
- Market Capitalization 1.06B
- Employee 145
- CEO Dr. Roger A. Jeffs Ph.D.
- Headquarters Morrisville,NC,US
- IPO Date 2018-07-26
-
Website
https://www.liquidia.com 
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
